A Phase 1 interventional study of PF-04965842 and Placebo in Healthy, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-06-20.
Sponsored by Pfizer · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This single- and multiple-ascending dose study is the first evaluation of PF-04965842, a Janus kinase1 (JAK1) inhibitor, in humans. The goal is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics in healthy Western and Japanese subjects.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: PF-04965842
Drug: Placebo
Drug: PF-04965842
Drug: Placebo
Drug: PF-04965842
Drug: Placebo
Drug: PF-04965842
Drug: Placebo
Drug: PF-04965842
Drug: Placebo
Subjects will receive single doses of 3, 10, 30, 100, 200, 400, or 800 mg of PF-04695842 (solution or suspension) in a dose escalation format.
Subjects will receive single doses of PF-04695842 matching placebo (solution or suspension) in a dose escalation format.
Subjects will receive doses of 30, 100 or 200 mg (solution or suspension) once daily for 10 days.
Subjects will receive PF-04965842 matching placebo (solution or suspension) once daily for 10 days.
Subjects will receive doses of 100 or 200 mg (suspension or solution) twice daily for 10 days.
Subjects will receive PF-04965842 matching placebo doses (suspension or solution) twice daily for 10 days.
Subjects will receive 200 mg dose (suspension or solution) twice daily for 10 days.
Subjects will receive PF-04965842 matching placebo dose (suspension or solution) twice daily for 10 days.
Subjects will receive 400 mg dose (suspension or solution) once daily for 10 days.
Subjects will receive PF-04965842 matching placebo dose (suspension or solution) once daily for 10 days.
Changes from baseline vital signs (blood pressure, pulse rate, oral temperature and respiration rate) and physical examinations
Time frame: 6 weeks
Changes from baseline in 12 lead ECG parameters
Quantitative changes in ECG intervals
Time frame: 6 weeks
Incidence and severity of treatment emergent adverse events and withdrawals due to treatment emergent adverse events
Time frame: 6 weeks
Incidence and magnitude of treatment emergent clinical laboratory abnormalities including hematology (with white blood cell count differentials, platelets, PT and aPTT), chemistry, fasting glucose, urinalysis
Time frame: 6 weeks
Change from baseline in immunoglobulin levels
Quantitative IgG, IgA, IgM, and IgE levels
Time frame: 6 weeks
24-hour urine creatinine clearance (Single Ascending Dose Period)
Time frame: Baseline, Day 1
24-hour urine creatinine clearance (Multiple Ascending Dose Period)
Time frame: Baseline, Day 1
Complement Level: C3
Time frame: 6 weeks
Complement Level: C4
Time frame: 6 weeks
Complement Level: C3A
Cohorts 1-7 and Cohort 9
Time frame: 6 weeks
Complement Level: Bb
Cohorts 1-7 and Cohort 9
Time frame: 6 weeks
Single Ascending Dose: Dose-normalized Area Under the Curve From Time Zero to Infinity (AUCinf(dn))
Time frame: 8 days
Multiple Ascending Dose: Accumulation Ratio based on Cmax (Rac(Cmax))
Time frame: 6 weeks
Urinary Pharmacokinetics; for twice-a-day dosing, amount of PF-0496842 excreted unchanged in 12 hours (AE12)
Time frame: 6 weeks
Urinary Pharmacokinetics; for twice-a-day dosing, percent of PF-0496842 excreted unchanged in 12 hours (AE12%)
Time frame: 6 weeks
Multiple Ascending Dose: Apparent Volume of Distribution at Steady State (Vz/F)
Vz/F is the distribution of a drug between plasma and the rest of the body following oral adminstration.
Time frame: 6 weeks
Multiple Ascending Dose: Apparent Total Body Clearance (CL/F)
Time frame: 6 weeks
Urinary Pharmacokinetics; for once-a-day dosing, amount of PF-0496842 excreted unchanged in 24 hours (AE24)
Time frame: 6 weeks
Urinary Pharmacokinetics; for once-a-day dosing, percent of PF-0496842 excreted unchanged in 24 hours (AE24%)
Time frame: 6 weeks
Renal Clearance (CLr)
Time frame: 6 weeks
High-Sensitivity C-Reactive Protein (hsCRP)
Time frame: 6 weeks
Neutrophil counts
Time frame: 6 weeks
Reticulocyte counts
Time frame: 6 weeks
Complement Level: CH50
Time frame: 6 weeks
Single Ascending Dose: Apparent Total Body Clearance (CL/F)
Time frame: 8 days
Multiple Ascending Dose: Maximum Observed Plasma Concentration (Cmax)
Time frame: 6 weeks
Multiple Ascending Dose: Time to Reach Maximum Observed Plasma Concentration (Tmax)
Time frame: 6 weeks
Multiple Ascending Dose: Dose-normalized Maximum Observed Plasma Concentration (Cmax(dn))
Time frame: 6 weeks
Multiple Ascending Dose: Area Under the Curve to the end of the dosing period (AUCtau(dn))
Time frame: 6 weeks
Multiple Ascending Dose: Accumulation Ratio based on AUC predicted (Rss)
Time frame: 6 weeks
Multiple Ascending Dose: Accumulation Ration based on AUC observed (Rac)
Time frame: 6 weeks
Multiple Ascending Dose: Plasma Decay Half-Life (t1/2)
Plasma decay half-life is the time measured for the plasma concentration to decrease by one-half.
Time frame: 6 weeks
Multiple Ascending Dose: Peak to Trough Fluctuation (PTF)
Time frame: 6 weeks
Single Ascending Dose: Dose-normalized Area Under the Curve to the end of the dosing period (AUCtau(dn))
Time frame: 8 days
Single Ascending Dose: Area Under the Curve From Time Zero to Infinity (AUCinf)
Time frame: 8 days
Single Ascending Dose: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)
Time frame: 8 days
Single Ascending Dose: Dose-normalized Maximum Observed Plasma Concentration (Cmax(dn))
Time frame: 8 days
Single Ascending Dose: Area Under the Curve to the end of the dosing period (AUCtau)
Time frame: 8 days
Single Ascending Dose: Dose-normalized Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast(dn))
Dose-normalized area under the plasma concentration time-curve from zero to the last measured concentration (AUClast(dn))
Time frame: 8 days
Single Ascending Dose: Plasma Decay Half-Life (t1/2)
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
Time frame: 8 days
Multiple Ascending Dose: Area Under the Curve to the end of the dosing period (AUCtau)
Time frame: 6 weeks
Single Ascending Dose: Apparent Volume of Distribution (Vz/F)
Time frame: 8 days
Single Ascending Dose: Maximum Observed Plasma Concentration (Cmax)
Time frame: 8 days
The record gives a start of May 2013, a primary completion of Jun 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abrocitinib